Personalized treatment for advanced colorectal cancer: KRAS and beyond

References

• DienstmannRVilarETaberneroJMolecular predictors of response to chemotherapy in colorectal cancerCancer J201117211412621427555
   PubMed Web of Science ®Google Scholar
• FearonERVogelsteinBA genetic model for colorectal tumorigenesisCell19906157597672188735
   PubMed Web of Science ®Google Scholar
• BolandCRGoelAMicrosatellite instability in colorectal cancerGastroenterology2010138620732087. e320420947
   PubMed Web of Science ®Google Scholar
• ToyotaMAhujaNOhe-ToyotaMHermanJGBaylinSBIssaJPCpG island methylator phenotype in colorectal cancerProc Natl Acad Sci U S A199996158681868610411935
   PubMed Web of Science ®Google Scholar
• GoelAArnoldCNNiedzwieckiDFrequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancersCancer Res20046493014302115126336
   PubMed Web of Science ®Google Scholar
• GoelAArnoldCNTassonePEpigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancersInt J Cancer2004112575475915386381
   PubMed Web of Science ®Google Scholar
• ShinSKNagasakaTJungBHEpigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancerGastroenterology200713361849185718054557
   PubMed Web of Science ®Google Scholar
• SilverASenguptaNPropperDA distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancersInt J Cancer201213051082109221455990
   PubMed Web of Science ®Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy GroupExpectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trialJ Clin Oncol19921069049111588370
   PubMed Web of Science ®Google Scholar
• ScheithauerWRosenHKornekGVSebestaCDepischDRandomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancerBMJ199330668807527557683942
   PubMed Web of Science ®Google Scholar
• TournigandCAndreTAchilleEFOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol200422222923714657227
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med2004351433734515269313
   PubMed Web of Science ®Google Scholar
• WeickhardtAJWilliamsDLeeCVascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX studyJ Clin Oncol201129Suppl3531
   Google Scholar
• SyrigosKNKarapanagiotouEBouraPManegoldCHarringtonKBevacizumab-induced hypertension: pathogenesis and managementBioDrugs201125315916921627340
   PubMed Web of Science ®Google Scholar
• Committee ACNCCGRGuidelines for the prevention, early detection and management of colorectal cancerNetwork TCCAaACSydney2005
   Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol20012212713711252954
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med2009360141408141719339720
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• ChungKYShiaJKemenyNECetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryJ Clin Oncol20052391803181015677699
   PubMed Web of Science ®Google Scholar
• MoroniMVeroneseSBenvenutiSGene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort studyLancet Oncol20056527928615863375
   PubMed Web of Science ®Google Scholar
• CappuzzoFFinocchiaroGRossiEEGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patientsAnn Oncol200819471772317974556
   PubMed Web of Science ®Google Scholar
• Sartore-BianchiAMoroniMVeroneseSEpidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumabJ Clin Oncol200725223238324517664472
   PubMed Web of Science ®Google Scholar
• Sartore-BianchiAFieuwsSVeroneseSStandardisation of EGFR FISH in colorectal cancer: results of an international interlabora-tory reproducibility ring studyJ Clin Pathol201265321822322130903
   PubMed Web of Science ®Google Scholar
• ScartozziMBearziIMandolesiAEpidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysisBMC Cancer2009930319712476
   PubMed Web of Science ®Google Scholar
• KuramochiHNakajimaGKanekoYAmphiregulin and epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastasesBMC Cancer2012128822409860
   PubMed Web of Science ®Google Scholar
• Khambata-FordSGarrettCRMeropolNJExpression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabJ Clin Oncol200725223230323717664471
   PubMed Web of Science ®Google Scholar
• JacobsBDe RoockWPiessevauxHAmphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximabJ Clin Oncol200927305068507419738126
   PubMed Web of Science ®Google Scholar
• TaberneroJCervantesARiveraFPharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation studyJ Clin Oncol20102871181118920100964
   PubMed Web of Science ®Google Scholar
• JonkerDJKarapetisCSHarbisonCTHigh epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from the NCIC CTG CO.17 – a phase III trial of cetuximab versus best supportive care (BSC)J Clin Oncol200927Suppl 154016
   Web of Science ®Google Scholar
• SchubbertSShannonKBollagGHyperactive Ras in developmental disorders and cancerNat Rev Cancer20077429530817384584
   PubMed Web of Science ®Google Scholar
• BosJLFearonERHamiltonSRPrevalence of ras gene mutations in human colorectal cancersNature198732761202932973587348
   PubMed Web of Science ®Google Scholar
• BosJLRas Oncogenes in human cancer: a reviewCancer Res19894917468246892547513
   PubMed Web of Science ®Google Scholar
• KnijnNMekenkampLJKlompMKRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patientsBr J Cancer201110461020102621364579
   PubMed Web of Science ®Google Scholar
• SantiniDLoupakisFVincenziBHigh concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practiceOncologist200813121270127519056857
   PubMed Web of Science ®Google Scholar
• ArtaleSSartore-BianchiAVeroneseSMMutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancerJ Clin Oncol200826254217421918757341
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJ Clin Oncol201028314697470520921465
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol201028314706471320921462
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med2008359171757176518946061
   PubMed Web of Science ®Google Scholar
• AllegraCJJessupJMSomerfieldMRAmerican Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapyJ Clin Oncol200927122091209619188670
   PubMed Web of Science ®Google Scholar
• BokemeyerCBondarenkoIHartmannJTEfficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnn Oncol20112271535154621228335
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHLangICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol201129152011201921502544
   PubMed Web of Science ®Google Scholar
• BokemeyerCVan CutsemERougierPAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsEur J Cancer201248101466147522446022
   PubMed Web of Science ®Google Scholar
• MaughanTSAdamsRASmithCGAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialLancet201037797832103211421641636
   PubMed Web of Science ®Google Scholar
• TveitKGurenTGlimeliusBRandomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation GroupAnn Oncol201021Suppl 8viii9
   Google Scholar
• BokemeyerCBondarenkoIMakhsonAFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol200927566367119114683
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerN Engl J Med2009360656357219196673
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol200927567268019114685
   PubMed Web of Science ®Google Scholar
• SobreroAFMaurelJFehrenbacherLEPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancerJ Clin Oncol200826142311231918390971
   PubMed Web of Science ®Google Scholar
• LangerCKopitJAwadMAnalysis of KRAS mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: results from the EPIC trialAnn Oncol200819Suppl 8viii133
   Google Scholar
• JimenoAMessersmithWAHirschFRFranklinWAEckhardtSGKRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selectionJ Clin Oncol20092771130113619124802
   PubMed Web of Science ®Google Scholar
• MolinariFFelicioniLBuscarinoMIncreased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancerClin Cancer Res201117144901491421632860
   PubMed Web of Science ®Google Scholar
• GuerreroSCasanovaIFarreLMazoACapellaGManguesRK-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpressionCancer Res200060236750675611118062
   PubMed Web of Science ®Google Scholar
• De RoockWJonkerDJDi NicolantonioFAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabJAMA2010304161812182020978259
   PubMed Web of Science ®Google Scholar
• TejparSCelikISchlichtingMSartoriusUBokemeyerCVan CutsemEAssociation of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabJ Clin Oncol201230293570357722734028
   PubMed Web of Science ®Google Scholar
• PeetersMDouillardJYVan CutsemEMutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumabJ Clin Oncol20201331675976523182985
   PubMed Web of Science ®Google Scholar
• BardelliASienaSMolecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancerJ Clin Oncol20102871254126120100961
   PubMed Web of Science ®Google Scholar
• LinardouHDahabrehIJKanaloupitiDAssessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerLancet Oncol200891096297218804418
   PubMed Web of Science ®Google Scholar
• De RoockWClaesBBernasconiDEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisLancet Oncol201011875376220619739
   PubMed Web of Science ®Google Scholar
• SeymourMTBrownSRRichmanSMiddletonGWMaughanTOlivierCAddition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC)J Clin Oncol201129Suppl352321825262
   PubMed Web of Science ®Google Scholar
• De Mattos-ArrudaLDienstmannRTaberneroJDevelopment of molecular biomarkers in individualized treatment of colorectal cancerClin Colorectal Cancer201110427928921729679
   PubMed Web of Science ®Google Scholar
• TieJGibbsPLiptonLOptimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF (V600E) mutationInt J Cancer201112892075208420635392
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• Di NicolantonioFMartiniMMolinariFBRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancerEur J Cancer Suppl200861281
   Web of Science ®Google Scholar
• TaberneroJKonneCO’DwyerPJA phase IIB double-blind, randomized study evaluating the efficacy and safety of sorafenib (SOR) compared with placebo (PBO) when administered in combination with chemotherapy (modified FOLFOX6) for first-line treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). The RESPECT TrialEur J Cancer201147Suppl 211
   Web of Science ®Google Scholar
• KopetzSDesaiJChanEPLX4032 in metastatic colorectal cancer patients with mutant BRAF tumoursJ Clin Oncol201028Suppl 153534
   Web of Science ®Google Scholar
• ChapmanPPuzanovISosmanJEarly efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032Eur J Cancer Suppl2009735
   Web of Science ®Google Scholar
• Sartore-BianchiAMartiniMMolinariFPIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodiesCancer Res20096951851185719223544
   PubMed Web of Science ®Google Scholar
• FrattiniMSalettiPRomagnaniEPTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBr J Cancer20079781139114517940504
   PubMed Web of Science ®Google Scholar
• JhawerMGoelSWilsonAJPIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximabCancer Res20086861953196118339877
   PubMed Web of Science ®Google Scholar
• LoupakisFPollinaLStasiIPTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerJ Clin Oncol200927162622262919398573
   PubMed Web of Science ®Google Scholar
• PrenenHDe SchutterJJacobsBPIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancerClin Cancer Res20091593184318819366826
   PubMed Web of Science ®Google Scholar
• BrunnerTBHahnSMGuptaAKMuschelRJMcKennaWGBernhardEJFarnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigationsCancer Res200363185656566814522880
   PubMed Web of Science ®Google Scholar
• Van CutsemEvan de VeldeHKarasekPPhase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerJ Clin Oncol20042281430143815084616
   PubMed Web of Science ®Google Scholar
• SolitDBGarrawayLAPratilasCABRAF mutation predicts sensitivity to MEK inhibitionNature2006439707435836216273091
   PubMed Web of Science ®Google Scholar
• WeeSJaganiZXiangKXPI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancersCancer Res200969104286429319401449
   PubMed Web of Science ®Google Scholar
• MirzoevaOKDasDHeiserLMBasal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibitionCancer Res200969256557219147570
   PubMed Web of Science ®Google Scholar
• PrahalladASunCHuangSUnresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFRNature2012483738710010322281684
   PubMed Web of Science ®Google Scholar
• YonesakaKZejnullahuKOkamotoIActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabSci Transl Med201139999ra86
   PubMed Web of Science ®Google Scholar
• BertottiAMigliardiGGalimiFA molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerCancer Discov20111650852322586653
   PubMed Web of Science ®Google Scholar
• VecchioneLJacobsBNormannoNCiardielloFTejparSEGFR-targeted therapyExp Cell Res2011317192765277121925171
   PubMed Web of Science ®Google Scholar
• ArnolettiJPBuchsbaumDJHuangZQMechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cellsJ Gastrointest Surg200488960969 discussion 969–97015585383
   PubMed Web of Science ®Google Scholar
• ScartozziMMandolesiAGiampieriRThe role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximabOncologist2011161536021212430
   PubMed Web of Science ®Google Scholar
• ScartozziMMandolesiAGiampieriRInsulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecanInt J Cancer201012781941194720099280
   PubMed Web of Science ®Google Scholar
• CappuzzoFVarella-GarciaMFinocchiaroGPrimary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsBr J Cancer2008991838918577988
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• Bonine-SummersARAakreMEBrownKAEpidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cellsCancer Biol Ther20076456157017495520
   PubMed Web of Science ®Google Scholar
• KammulaUSKuntzEJFranconeTDMolecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcomeCancer Lett2007248221922816945480
   PubMed Web of Science ®Google Scholar
• PiessevauxHBuyseMDe RoockWRadiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)Ann Oncol20092081375138219465422
   PubMed Web of Science ®Google Scholar
• De RoockWPiessevauxHDe SchutterJKRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnn Oncol200819350851517998284
   PubMed Web of Science ®Google Scholar
• GrotheyAHedrickEEMassRDResponse-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107J Clin Oncol200826218318918182660
   PubMed Web of Science ®Google Scholar
• PiessevauxHSchlichtlingMHeegerSvan CutsemETejparSEarly tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (MCRC): analysis from the CRYSTAL studyAnn Oncol201021Suppl 8viii193
   Google Scholar
• PatelGSKiuchiTLawlerKThe challenges of integrating molecular imaging into the optimization of cancer therapyIntegr Biol (Camb)20113660363121541433
   PubMed Web of Science ®Google Scholar
• PalAGlekasADoubrovinMMolecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomographyMol Imaging Biol20068526227716897320
   PubMed Web of Science ®Google Scholar
• HadjipanayisCGMachaidzeRKaluzovaMEGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastomaCancer Res201070156303631220647323
   PubMed Web of Science ®Google Scholar
• SouglakosJKalykakiAVamvakasLPhase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapyAnn Oncol200718230531017079693
   PubMed Web of Science ®Google Scholar
• LenzHJVan CutsemEKhambata-FordSMulticenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesJ Clin Oncol200624304914492117050875
   PubMed Web of Science ®Google Scholar
• SaltzLBMeropolNJLoehrerPJSrNeedleMNKopitJMayerRJPhase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptorJ Clin Oncol20042271201120814993230
   PubMed Web of Science ®Google Scholar
• PeetersMSienaSVan CutsemEAssociation of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab mono-therapyCancer200911571544155419189371
   PubMed Web of Science ®Google Scholar
• Van CutsemETejparSVanbeckevoortDIntrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST studyJ Clin Oncol201230232861286822753904
   PubMed Web of Science ®Google Scholar
• DignamJJPoliteBNYothersGBody mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancerJ Natl Cancer Inst200698221647165417105987
   PubMed Web of Science ®Google Scholar
• MeyerhardtJANiedzwieckiDHollisDImpact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803J Clin Oncol200826254109411518757324
   PubMed Web of Science ®Google Scholar
• GuiuBPetitJMBonnetainFVisceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancerGut201059334134719837679
   PubMed Web of Science ®Google Scholar
• LimsuiDVierkantRATillmansLSCigarette smoking and colorectal cancer risk by molecularly defined subtypesJ Natl Cancer Inst2010102141012102220587792
   PubMed Web of Science ®Google Scholar
• ChuaWCharlesKABaracosVEClarkeSJNeutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancerBr J Cancer201110481288129521448173
   PubMed Web of Science ®Google Scholar
• VincenziBGalluzzoSSantiniDEarly magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patientsAnn Oncol20112251141114621115601
   PubMed Web of Science ®Google Scholar
• VickersMMKarapetisCSTuDThe influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17J Clin Oncol201129Suppl3601
   Web of Science ®Google Scholar
• GormallyEHainautPCabouxEAmount of DNA in plasma and cancer risk: a prospective studyInt J Cancer2004111574674915252845
   PubMed Web of Science ®Google Scholar
• GormallyECabouxEVineisPHainautPCirculating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significanceMutat Res20076352–310511717257890
   PubMed Web of Science ®Google Scholar
• LecomteTBergerAZinzindohoueFDetection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosisInt J Cancer2002100554254812124803
   PubMed Web of Science ®Google Scholar
• DiehlFLiMDressmanDDetection and quantification of mutations in the plasma of patients with colorectal tumorsProc Natl Acad Sci U S A200510245163681637316258065
   PubMed Web of Science ®Google Scholar
• DiehlFSchmidtKChotiMACirculating mutant DNA to assess tumor dynamicsNat Med200814998599018670422
   PubMed Web of Science ®Google Scholar
• SebtiSMDerCJOpinion: Searching for the elusive targets of farnesyltransferase inhibitorsNat Rev Cancer200331294595114737124
   PubMed Web of Science ®Google Scholar
• RowinskyEKLately, it occurs to me what a long, strange trip it’s been for the farnesyltransferase inhibitorsJ Clin Oncol200624192981298416769983
   PubMed Web of Science ®Google Scholar
• CalinGAFerracinMCimminoAA microRNA signature associated with prognosis and progression in chronic lymphocytic leukemiaN Engl J Med2005353171793180116251535
   PubMed Web of Science ®Google Scholar
• AkaoYNakagawaYNaoeTlet-7 microRNA functions as a potential growth suppressor in human colon cancer cellsBiol Pharm Bull200629590390616651716
   PubMed Web of Science ®Google Scholar
• ChenXGuoXZhangHRole of miR-143 targeting KRAS in colorectal tumorigenesisOncogene200928101385139219137007
   PubMed Web of Science ®Google Scholar
• MekenkampLJTolJDijkstraJRBeyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patientsBMC Cancer20121229222804917
   PubMed Web of Science ®Google Scholar
• DijkstraJRMekenkampLJTeerenstraSDe KrijgerINagtegaalIDMicroRNA expression in formalin-fixed paraffin embedded tissue using real time quantitative PCR: the strengths and pitfallsJ Cell Mol Med201216468369022003827
   PubMed Web of Science ®Google Scholar
• CalemmaROttaianoATrottaAMFc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcomeJ Transl Med20121023223171437
   PubMed Web of Science ®Google Scholar
• Van SchaeybroeckSAllenWLTurkingtonRCJohnstonPGImplementing prognostic and predictive biomarkers in CRC clinical trialsNat Rev Clin Oncol20118422223221321566
   PubMed Web of Science ®Google Scholar
• VilarEGruberSBMicrosatellite instability in colorectal cancer – the stable evidenceNat Rev Clin Oncol20107315316220142816
   PubMed Web of Science ®Google Scholar
• BertagnolliMMNiedzwieckiDComptonCCMicrosatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803J Clin Oncol200927111814182119273709
   PubMed Web of Science ®Google Scholar
• VallbohmerDYangDYKuramochiHDPD is a molecular determinant of capecitabine efficacy in colorectal cancerInt J Oncol200731241341817611699
   PubMed Web of Science ®Google Scholar
• KoopmanMVenderboschSvan TinterenHPredictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO studyEur J Cancer200945111999200619457654
   PubMed Web of Science ®Google Scholar
• AstsaturovIRatushnyVSukhanovaASynthetic lethal screen of an EGFR-centered network to improve targeted therapiesSci Signal20103140ra6720858866
   PubMed Web of Science ®Google Scholar